Interference between D30N and L90M in selection and development of protease inhibitor-resistant human immunodeficiency virus type 1

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 3, 2002, Pages 708-715

  Sugiura, Wataru ^a   Matsuda, Zene ^a   Yokomaku, Yoshiyuki ^a   Hertogs, Kurt ^a   Larder, Brendan ^a   Oishi, Tsuyoshi ^a   Okano, Aiko ^a   Shiino, Teiichirou ^a   Tatsumi, Masashi ^a   Matsuda, Masakazu ^a   Abumi, Hanae ^a   Takata, Noboru ^a   Shirahata, Satoshi ^a   Yamada, Kaneo ^a   Yoshikura, Hiroshi ^a   Nagai, Yoshiyuki ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINE; ASPARTIC ACID; DIDANOSINE; INDINAVIR; LAMIVUDINE; LEUCINE; METHIONINE; NELFINAVIR; PROTEIN PRECURSOR; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CASE REPORT; CONTROLLED STUDY; DRUG RESISTANCE; ENZYME ACTIVITY; GENE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MUTATION; NONHUMAN; PHYLOGENY; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RADIOIMMUNOPRECIPITATION; VIRUS INFECTIVITY; VIRUS LOAD; VIRUS REPLICATION;

CLONING, MOLECULAR; DRUG RESISTANCE, MICROBIAL; GENE PRODUCTS, GAG; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; KINETICS; MUTATION; PHYLOGENY; PROTEIN PRECURSORS; RNA, VIRAL; VIRUS REPLICATION;

EID: 0036168452     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.3.708-715.2002     Document Type: Article

References (34)

1. HIV-1 evolution under pressure of protease inhibitors: Climbing the stairs of viral fitness
2. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
3. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors
4. The HIV-1 protease as a therapeutic target for AIDS
5. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure
6. Testing for HIV-1 drug resistance: New developments and clinical implications
7. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society-USA Panel
8. Antiretroviral drug resistance testing in adults with HIV infection: Implications for clinical management. International AIDS Society-USA Panel
9. In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: Mutations, kinetics, and frequencies
10. Crystal structure of HIV-1 protease in complex with VX478, a potent and orally bioavailable inhibitor of the enzyme
11. Active human immunodeficiency virus protease is required for viral infectivity
12. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays
13. Complete mutagenesis of the HIV-1 protease
14. Structural and kinetic analysis of drug resistant mutants of HIV-1 protease
15. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: Phenotypic analysis of protease and Gag coevolution in protease inhibitor-treated patients
16. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection
17. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor
18. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection
19. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1
20. A virion-specific inhibitory molecule with therapeutic potential for human immunodeficiency virus type 1
21. An infectious DNA clone of HIV type 1 subtype C
22. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
23. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease
24. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir
25. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease
26. Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity
27. Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors
28. Rational design of peptidebased HIV proteinase inhibitors
29. Two possible pathways for acquisition of mutations related to nelfinavir resistance
30. L-735,524: An orally bioavailable human immunodeficiency virus type 1 protease inhibitor
31. The HIV type 1 protease inhibitor saquinavir can select for multiple mutations that confer increasing resistance
32. Molecular mechanics analysis of drug-resistant mutants of HIV protease
33. Drug resistance mutations can affect dimer stability of HIV-1 protease at neutral pH
34. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo